| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2161 | 2017 |
| Financial crisis, austerity, and health in Europe M Karanikolos, P Mladovsky, J Cylus, S Thomson, S Basu, D Stuckler, ... The lancet 381 (9874), 1323-1331, 2013 | 1977 | 2013 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1590 | 2018 |
| A proposed system for the nomenclature of hepatitis C viral genotypes P Simmonds, A Alberti, HJ Alter, F Bonino, DW Bradley, C Brechot, ... Hepatology 19 (5), 1321-1324, 1994 | 1344 | 1994 |
| Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen GR Simpson, TF Schulz, D Whitby, PM Cook, C Boshoff, L Rainbow, ... The Lancet 348 (9035), 1133-1138, 1996 | 694 | 1996 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 580 | 2008 |
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management AMJ Wensing, DA Van De Vijver, G Angarano, B Åsjö, C Balotta, E Boeri, ... The Journal of infectious diseases 192 (6), 958-966, 2005 | 558 | 2005 |
| Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel V Soriano, M Puoti, M Sulkowski, A Cargnel, Y Benhamou, M Peters, ... Aids 21 (9), 1073-1089, 2007 | 458 | 2007 |
| Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) ME Eyster, HJ Alter, LM Aledort, S Quan, A Hatzakis, JJ Goedert Annals of Internal Medicine 115 (10), 764-768, 1991 | 427 | 1991 |
| Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study TR O'Brien, WA Blattner, D Waters, ME Eyster, MW Hilgartner, AR Cohen, ... Jama 276 (2), 105-110, 1996 | 421 | 1996 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 407 | 2022 |
| Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel V Soriano, M Sulkowski, C Bergin, A Hatzakis, P Cacoub, C Katlama, ... Aids 16 (6), 813-828, 2002 | 397 | 2002 |
| Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma C Boschoff, D Whitby, T Hatziionnou, C Fisher, J van der Walt, A Hatzakis, ... The Lancet 345 (8956), 1043-1044, 1995 | 386 | 1995 |
| Management of antiviral resistance in patients with chronic hepatitis B S Locarnini, A Hatzakis, J Heathcote, EB Keeffe, TJ Liang, D Mutimer, ... Antiviral therapy 9 (5), 679-693, 2004 | 373 | 2004 |
| The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference A Hatzakis, S Wait, J Bruix, M Buti, M Carballo, M Cavaleri, M Colombo, ... Journal of viral hepatitis 18, 1-16, 2011 | 353 | 2011 |
| Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs S Locarnini, A Hatzakis, DS Chen, A Lok Journal of hepatology 62 (1), S76-S86, 2015 | 336 | 2015 |
| Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach JM Pawlotsky, G Dusheiko, A Hatzakis, D Lau, G Lau, TJ Liang, ... Gastroenterology 134 (2), 405-415, 2008 | 330 | 2008 |
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ... The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017 | 325 | 2017 |
| Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial AN Phillips, A Carr, J Neuhaus, F Visnegarwala, R Prineas, WJ Burman, ... Antiviral therapy 13 (2), 177-188, 2008 | 310 | 2008 |
| Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis GK Nikolopoulo, D Paraskevis, E Hatzitheodorou, Z Moschidis, V Sypsa, ... Clinical Infectious Diseases 48 (12), 1763-1771, 2009 | 289 | 2009 |
